Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 14/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28671526 | 1.00 | PIK3CD (0.49) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL28671527 | 1.00 | PIK3CD (0.49) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL20137579 | 0.85 | EGFR (0.41) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL20137580 | 0.85 | EGFR (0.41) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL29686112 | 0.83 | GPR119 (0.60) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL29686200 | 0.82 | PIK3CD (0.52) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL29079738 | 0.79 | GPR119 (0.56) | GPR119 | |
| SCHEMBL18089521 | 0.79 | GPR119 (0.58) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL28668694 | 0.79 | GPR119 (0.58) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL20147445 | 0.78 | RET (0.42) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| EP-4144735-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20220313676-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-3523302-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2022-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | PIK3CD 1807/4885PIK3CA 915/4885PIK3CB 1959/4885 |
| US-20220313676-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | PIK3CD 1807/4885PIK3CA 915/4885PIK3CB 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.